Study: NCT01021852

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-6096
Description: MK-6096 2.5 mg or 5 mg tablets equaling 2.5 mg dose, 5 mg dose, 10 mg dose, or 20 mg dose (depending upon allocation) were taken daily before bedtime for 4 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-6096
Description: MK-6096 2.5 mg or 5 mg tablets equaling 2.5 mg dose, 5 mg dose, 10 mg dose, or 20 mg dose (depending upon allocation) were taken daily before bedtime for 4 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-6096
Description: MK-6096 2.5 mg or 5 mg tablets equaling 2.5 mg dose, 5 mg dose, 10 mg dose, or 20 mg dose (depending upon allocation) were taken daily before bedtime for 4 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-6096
Description: MK-6096 2.5 mg or 5 mg tablets equaling 2.5 mg dose, 5 mg dose, 10 mg dose, or 20 mg dose (depending upon allocation) were taken daily before bedtime for 4 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-6096
Description: MK-6096 2.5 mg or 5 mg tablets equaling 2.5 mg dose, 5 mg dose, 10 mg dose, or 20 mg dose (depending upon allocation) were taken daily before bedtime for 4 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-6096
Description: MK-6096 2.5 mg or 5 mg tablets equaling 2.5 mg dose, 5 mg dose, 10 mg dose, or 20 mg dose (depending upon allocation) were taken daily before bedtime for 4 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-6096
Description: MK-6096 2.5 mg or 5 mg tablets equaling 2.5 mg dose, 5 mg dose, 10 mg dose, or 20 mg dose (depending upon allocation) were taken daily before bedtime for 4 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-6096
Description: MK-6096 2.5 mg or 5 mg tablets equaling 2.5 mg dose, 5 mg dose, 10 mg dose, or 20 mg dose (depending upon allocation) were taken daily before bedtime for 4 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dose-matched Placebo to MK-6096
Description: Dose-matched placebo tablets to MK-6096 were taken daily before bedtime during 2-week single-blind run-in, for 4 weeks as a treatment period, and during 2-week washout between treatment periods.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dose-matched Placebo to MK-6096
Description: Dose-matched placebo tablets to MK-6096 were taken daily before bedtime during 2-week single-blind run-in, for 4 weeks as a treatment period, and during 2-week washout between treatment periods.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dose-matched Placebo to MK-6096
Description: Dose-matched placebo tablets to MK-6096 were taken daily before bedtime during 2-week single-blind run-in, for 4 weeks as a treatment period, and during 2-week washout between treatment periods.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dose-matched Placebo to MK-6096
Description: Dose-matched placebo tablets to MK-6096 were taken daily before bedtime during 2-week single-blind run-in, for 4 weeks as a treatment period, and during 2-week washout between treatment periods.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dose-matched Placebo to MK-6096
Description: Dose-matched placebo tablets to MK-6096 were taken daily before bedtime during 2-week single-blind run-in, for 4 weeks as a treatment period, and during 2-week washout between treatment periods.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dose-matched Placebo to MK-6096
Description: Dose-matched placebo tablets to MK-6096 were taken daily before bedtime during 2-week single-blind run-in, for 4 weeks as a treatment period, and during 2-week washout between treatment periods.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dose-matched Placebo to MK-6096
Description: Dose-matched placebo tablets to MK-6096 were taken daily before bedtime during 2-week single-blind run-in, for 4 weeks as a treatment period, and during 2-week washout between treatment periods.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dose-matched Placebo to MK-6096
Description: Dose-matched placebo tablets to MK-6096 were taken daily before bedtime during 2-week single-blind run-in, for 4 weeks as a treatment period, and during 2-week washout between treatment periods.